ArticleFrontiers in surgery2025
The PEG-coated collagen patch Hemopatch® for hemostasis and dural sealing in neurosurgery.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Risk factors for extra-axial hemorrhage during invasive monitoring using subdural electrodes.Neurosurgical review · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative cerebrospinal fluid (CSF) leakage and bleeding are major postoperative complications that increase healthcare system costs. The use of Hemopatch® Sealing Hemostat has been shown to reduce the incidence of such postoperative complications. This technical report aims to provide neurosurgeons with the best recommendations for the effective use of Hemopatch® as a hemostatic and dural sealant in cranial and spinal procedures. Material and methods: The clinical experiences of 10 neurosurgeons from around the world regarding the use of Hemopatch® were evaluated using an online survey, followed by a hands-on preclinical workshop on adult pigs, which concluded with an in-depth discussion about the use of the patch. Results: The survey results provide an overview of how and when experts use different types of dural repair materials, including decision-making factors. During the workshop, Hemopatch® presented excellent tissue adherence on all evaluated defects. The new configuration of the patch showed improved tissue adherence, less curling of the patch, and easier removal of the gauze used for compression. Experts recommend using patches that overlap the defect for ≥1 cm. When closing defects that do not allow for a dried application site, Hemopatch® can be put on a dry gauze, which can be bent into a U-shape. This allows better targeting of the application site and enables immediate compression upon placement. Conclusion: The results provide information to improve the hands-on use of Hemopatch® as a dural sealant, therefore reducing the risk of postoperative complications such as CSF leaks, eventually reducing healthcare system costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.